SGLT2 Inhibitors May be "Optimal" Treatment for HFpEF, HFmrEF, a New Meta-analysis Suggests
SGLT-2 inhibitors and drugs to treat HFrEF were compared for efficacy in patients with HF with LVEF ≥40%.
ADA, EASD Release Update on Management of Hyperglycemia in Type 2 Diabetes
The new consensus recommends holistic, person centered care focused on glycemic and weight management, CV risk reduction, and cardiorenal organ protection.
T2D Patient Preference Survey Finds Low Side Effect Profile Outranks CVD Protection for Newer OADs
New survey findings suggest the need for more in-depth conversations with patients about benefits and harms of newer oral therapies for type 2 diabetes.
FreeStyle Libre 3 CGM Linked with Reduced Hospital Admissions in Patients with T2D
Hospital admissions among patients with T2D taking basal insulin only were reduced by 67% one year after beginning treatment with the CGM system.
Migraine with Aura Characterized as Independent Risk Factor for Atrial Fibrillation
Adults with migraine with aura were found at significantly greater risk for AF and those younger than age 55 years were particularly vulnerable, write Mayo Clinic investigators.
Patient Wait Time for a Family Practice Appointment: 15 Major US Cities Surveyed
Average patient wait time for a nonemergent appointment with an FP decreased between 2017 and 2020, according to a Merritt Hawkins survey. Is that a good sign?
Hypertension-related CVD Most Common ED Presentation in the US
Approximately one-third of CV-related ED visits are for hypertension-related conditions, including 13% for essential hypertension among women.
Intervention Reduces Aspirin Use in Patients with AF, VTE Taking Warfarin, Improves Outcomes
An aspirin deprescribing intervention at anticoagulation clinics led to a 50% reduction in use among patients with AF, VTE prescribed warfarin.
Semaglutide 2.4 mg: Weight Loss in Real-world Study Matches STEP Trial Program Findings
Semaglutide prescribed in clinical practice helped more than half of study participants achieve weight loss of ≥10% at 6 months.
"Long COVID is Not Anxiety," but that Was an Early Hypothesis
Long COVID is now recognized as real, in the medical community and in Washington, DC, but 2 years ago it was a different story, says AAPM&R's Steven Flanagan, MD.
Tirzepatide Reduces Time to HbA1c Targets by Up to 3 Months vs Semaglutide, Insulin Degludec
Tirzepatide in an exploratory analysis of SURPASS-2 and -3 trials added proof of shorter time to glycemic targets and weight loss goals to superior reduction of HbA1c.
The Brunt of the Long COVID Patient Burden May Fall on Primary Care, says Rehabilitation Medicine Expert
NYU Langone Rusk Rehabilitation medical director Steven Flanagan, MD, discusses the "second crisis" of the pandemic and the impact on primary care.
COPD: Pulmonary Rehab is Effective Regardless of Inhaled Triple Therapy Use
In-hospital pulmonary rehabilitation improves function and symptoms in COPD patients whether they are on triple therapy or not, a new study confirms.
Finerenone: FDA Expands Label to Include Cardiovascular Outcomes Trial Data
Data from the pivotal phase 3 FIGARO-DKD cardiovascular outcomes trial with finerenone reaffirms the agent's dual cardiorenal risk reduction benefits in T2D-associated CKD.
Long COVID Presents Many More Questions than Answers, says AAPM&R President-elect Flanagan
Long COVID symptoms are reported by persons who have had only mild disease, who have been vaccinated and boosted, and even those who had asymptomatic infection.
Cumulative Load of Systolic BP May Better Predict CV Risk in T2D Patients vs Standard BP Measures
In patients with type 2 diabetes, for every standard deviation increase in cumulative SBP load there was an increase of at least 10% in CV risk, a new study found.
The "Ugly Face" of Long COVID: A Conversation with Steven Flanagan, MD, President-elect, AAPM&R
The American Academy of Physical Medicine and Rehabilitation is a leading voice in the campaign for a national plan to address long COVID.
Early-onset Type 2 Diabetes Linked to Significantly Increased Risk for CVD in Later Life: Study
A 5-fold greater risk for all-cause or CVD-related death in persons diagnosed with T2D before age 40 years should be a call to action for enhanced screening, study authors state.
Decline in Physical Function Independently Associated with CVD Risk in Older Adults: ARIC Analysis
Physical performance scores used as a proxy for function in adults aged >65 years improved CVD risk prediction beyond traditional risk factors, study authors report.
Artificial Sweetener Intake Linked to Increased Risk of CVD in Large, Population-based Analysis
Artificial sweeteners should not be considered a healthy and safe alternative to sugar, caution French investigators.
Hypertension Treatment is Cost-effective for CVD Prevention, Whether the Target is from ACC/AHA or JNC 7, Study Reveals
Reducing blood pressure to 140/90 mm Hg or 130/80 mm Hg in high-risk patients proved either cost-saving or cost-effective at 10 years in a simulation study.
Education on Use of ABPM Data Needed in Primary Care to Avoid Misdiagnosis of Hypertension
AHA Hypertension 2022. Half of patients with newly elevated BP had white coat HTN yet some were diagnosed with HTN at next primary care visit, new study finds.
DASH Diet, Weight Loss, Exercise and Other Nondrug Strategies to Manage Hypertension
Find out how effective these 3 and 5 additional ACC/AHA-recommended non-drug interventions are at reducing BP (in mm Hg) in adults with hypertension and with normal BP.
High HDL-C Increases CV Risk in Men with Hypertension, Study Finds
In patients with hypertension, HDL-C >80 mg/dL was linked to a greater risk for CV events among men but not among women. Protective?
FDA Authorizes Pfizer and Moderna Updated COVID-19 Booster Shots
The FDA EUA amendments for updated booster vaccinations are based on clinical studies of the omicron BA.1 variant and preclinical data on the BA.4 and BA.5 variants.
Polypill Reduces Risk of MACE in Secondary Prevention for Older Adults: Results from SECURE
Taking a 3-drug polypill (aspirin, ACEi, statin) vs each of the drugs separately reduced risk for a major CV event by 33%, according to results of the SECURE trial.
The Future of US Antimicrobial Resistance is in Our Hands and There is Work to Do
Steer clear of antibiotic Rxs whenever possible, says Anne Meneghetti, MD, to help the US get back to pre-COVID levels of antimicrobial stewardship.
8 Key Drivers of Hypertension Control & How to Improve Them
These 8 drivers of BP control reflect study of high-performing health systems and the strategies that have led to successful large scale hypertension management.
Primary Care Can Help Restore US Antibiotic Stewardship, Starting with Flu Shots
Preventing viral infections with vaccination can keep the most vulnerable out of the hospital, reducing the risk of bacterial superinfections.
Superinfection Rate in Hospitalized COVID-19 Patients was Found to be Low
Only 9% of inpatients with COVID-19 had a bacterial superinfection that could be treated with antibiotics which curbed use of broad-spectrum antimicrobials.